Media headlines about GlaxoSmithKline (NYSE:GSK) have trended somewhat positive recently, according to Accern. The research firm identifies negative and positive press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. GlaxoSmithKline earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave headlines about the pharmaceutical company an impact score of 46.6408266948909 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:

Shares of GlaxoSmithKline (NYSE:GSK) traded up $0.44 during trading on Thursday, hitting $36.84. The company had a trading volume of 4,567,386 shares, compared to its average volume of 6,198,697. The company has a debt-to-equity ratio of 2.96, a quick ratio of 0.44 and a current ratio of 0.64. The company has a market capitalization of $90,420.00, a P/E ratio of 28.78, a PEG ratio of 2.15 and a beta of 0.97. GlaxoSmithKline has a one year low of $34.52 and a one year high of $44.53.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, January 11th. Investors of record on Friday, November 10th will be issued a dividend of $0.5037 per share. This represents a $2.01 dividend on an annualized basis and a dividend yield of 5.47%. The ex-dividend date of this dividend is Thursday, November 9th. This is an increase from GlaxoSmithKline’s previous quarterly dividend of $0.49. GlaxoSmithKline’s dividend payout ratio is currently 159.38%.

A number of research firms have recently weighed in on GSK. JPMorgan Chase & Co. reissued a “neutral” rating on shares of GlaxoSmithKline in a research note on Thursday. Zacks Investment Research lowered GlaxoSmithKline from a “buy” rating to a “hold” rating in a research note on Wednesday. ValuEngine lowered GlaxoSmithKline from a “buy” rating to a “hold” rating in a research note on Sunday, December 31st. Investec lowered GlaxoSmithKline from a “buy” rating to a “hold” rating in a research note on Monday, November 6th. Finally, Bank of America lowered GlaxoSmithKline from a “buy” rating to a “neutral” rating in a research note on Thursday, October 26th. Three equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $38.57.

In other GlaxoSmithKline news, major shareholder Plc Glaxosmithkline bought 428,571 shares of the firm’s stock in a transaction that occurred on Monday, November 6th. The stock was bought at an average price of $14.00 per share, for a total transaction of $5,999,994.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 10.00% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at

GlaxoSmithKline Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Insider Buying and Selling by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with's FREE daily email newsletter.